How Bespoke Production Chemicals Outperform Catalogue Solutions

I have spent the better part of two decades watching operators pour catalogue chemistry into reservoirs that have nothing in common with the brine matrices those products were screened against. It usually works, in the same way that a generic antibiotic usually works. The question is whether 'usually' is the right standard for a $40 million well intervention or a 200,000-barrel-per-day water-injection scheme.

The premise of bespoke production chemistry is unfashionable to state plainly: most of the value sits in formulation choices made before the first drum is shipped. Once a generic scale inhibitor or corrosion package is on a purchase order, the operator is essentially renting performance. Every change in temperature, salinity, or H2S partial pressure that the field throws at it erodes that performance, and the supplier's only lever is to recommend a higher dose rate.

Catalogue chemistry is screened, not designed

When I was at Saudi Aramco's Advanced Research Centre running the production chemistry programme, we benchmarked dozens of commercial products against produced waters from fields ranging from the Khurais complex to onshore Manifa. Almost every catalogue product had been screened against a synthetic brine that bore only passing resemblance to the field's actual ionic composition. Phosphonate scale inhibitors that performed beautifully on a North Sea-style barium sulphate scenario lost half of their threshold inhibition when challenged with the calcium-rich, low-sulphate brines we were dealing with.

Screening is not design. A vendor with a catalogue runs your brine sample through their existing inventory and recommends the closest fit. A bespoke chemist starts with the brine, the temperature gradient, the shear regime in the flowline, and the failure mode you are actually trying to suppress, and works backwards to a molecular structure. Those are different disciplines, and they produce different molecules.

"The catalogue is a list of what worked somewhere else. The reservoir does not care."

— From a 2016 internal review I wrote on chemical performance variance

Where bespoke pays back: four failure modes

Across roughly 50 patents and a hundred peer-reviewed papers, the same four failure modes account for most of the avoidable production loss I have seen in GCC fields. In each, the gap between catalogue and bespoke chemistry is measurable in dollars per barrel.

• Scale control in mixed-anion brines, where catalogue phosphonates compete with carbonate and silicate species and the effective inhibitor concentration at the formation face is a fraction of the injected dose.
• Top-of-line corrosion in wet-gas systems, where film-forming amines selected on rotating-cage tests fail to redistribute under stratified flow and leave the 12 o'clock position of the line essentially unprotected.
• Paraffin and asphaltene deposition in long tiebacks, where pour-point depressants tuned to a generic crude shift the wax appearance temperature by two or three degrees rather than the eight or nine the field actually needs.
• Water-injection souring and biofilm-driven MIC, where catalogue biocides hit planktonic counts on a coupon test but never penetrate the sessile community in the near-wellbore region.

In each case, the catalogue product is not wrong. It is simply not the answer to the question the field is asking. And once it is in the system, the only feedback the operator gets is a slow drift in production data that nobody attributes to chemistry until a workover bill arrives.

What 'bespoke' actually means in our practice

There is a fair amount of marketing slippage around the word bespoke. In our work at SMART Chemical and as Aontas Advisory's chemistry design partner, it has a specific meaning: the molecule, the carrier solvent, and the injection strategy are designed together against a named reservoir, with field-representative testing before a single drum leaves the plant.

Concretely, that means we start every engagement with a brine and crude characterisation that goes well beyond the standard ions. We measure organic acid speciation, transition-metal content, dissolved gas partial pressures at the relevant nodes, and the shear history the chemistry will see between injection point and the formation face. Only then do we open the question of which chemistry family to pursue.

The second discipline is field-representative testing. A dynamic scale loop run at reservoir temperature and pressure, with the actual brine and a realistic pH trajectory, will tell you in two weeks what a year of bottle tests will not. The same goes for high-temperature, high-pressure autoclave work for corrosion inhibitors and rocking-cell tests for asphaltene dispersants. The capital cost of running these tests properly is trivial compared with the operating cost of a misapplied chemistry.

A field example: rethinking a scale package

One of the engagements I am most often asked about involved a mature carbonate field where the operator was burning through scale inhibitor at roughly three times the dose rate the original commissioning study had predicted. The catalogue product, a perfectly reputable phosphonate blend, had been selected on the basis of a synthetic brine that omitted the field's actual zinc and iron content. Trace metals were complexing the inhibitor and stripping it out of solution before it reached the wellbore.

We redesigned the molecule with a sulphonated backbone that tolerated the divalent metal load, paired it with a sequestering co-additive, and changed the squeeze design to match the actual rock wettability. The dose rate dropped by sixty per cent, the squeeze life roughly doubled, and the operator stopped scheduling acid jobs that had been running every nine months for years. None of that was visible in the catalogue product's spec sheet because the catalogue product had never been tested against that brine.

Why GCC operators in particular pay a catalogue tax

The GCC produces some of the most chemically demanding reservoirs in the world: high temperatures, high salinities, often high H2S, and increasingly aggressive water cuts as the big mature fields move into late-life. The major catalogue houses develop their core chemistries against North Sea, Gulf of Mexico, and West African analogues, where the operating envelope is genuinely different.

I have seen this pattern repeatedly with Aramco assets, with ADNOC's Upper Zakum and Bab developments, and with KOC's Burgan complex. The catalogue product is not a bad product. It is a product designed somewhere else, sold here, and then asked to do work it was not formulated for. The result is that GCC operators routinely pay a premium of fifteen to thirty per cent in chemical opex over what a properly tuned formulation would cost, and they pay it without ever seeing the line item.

"If you cannot trace your inhibitor's structure to a decision someone made about your reservoir, you are paying for someone else's reservoir."

The commercial argument operators rarely make

There is a quiet objection to bespoke work that I hear in nearly every operator meeting: the catalogue is cheaper per litre. That is true and largely irrelevant. Production chemistry is not a litre business; it is a barrels-protected business. A $4-per-litre catalogue inhibitor that requires a 40 ppm dose rate is more expensive per barrel of protected production than a $9-per-litre tuned molecule running at 8 ppm, and it usually fails earlier.

Across the technologies I commercialised at Aramco, which generated more than $500 million in attributable value, the consistent pattern was that the upfront design effort was repaid within the first squeeze cycle or the first six months of continuous injection. The two World Oil Awards we received for production chemistry innovation were not for cheaper products; they were for products whose total cost of ownership was an order of magnitude better than the catalogue alternative.

How to know if your field has a catalogue problem

• Dose rates have crept up over the past 24 months without a corresponding change in produced-water chemistry on paper.
• Squeeze lifetimes are shorter than the original commissioning model predicted, and nobody has rebuilt the model.
• Corrosion coupons in different parts of the system show wildly different metal loss, suggesting the inhibitor film is not redistributing as designed.
• Your supplier's last technical visit produced a recommendation to increase concentration rather than to revisit the formulation.
• Nobody on the operator side can tell you what the active backbone of your inhibitor actually is.

Any two of those signals is enough to justify a formulation review. All five and the field is almost certainly leaving meaningful production on the table.

The shape of a better engagement

When Aontas Advisory engages on bespoke chemistry, the work is sequenced deliberately. First, a rigorous characterisation of the produced fluids and the failure mode in question. Second, a candidate-molecule design phase in which we narrow the chemistry family against the actual operating envelope. Third, field-representative laboratory validation. Fourth, a small-scale field trial with proper sampling and a defined success criterion. Only then do we move to full deployment and supply.

That sequence is unglamorous. It is also the difference between chemistry that ages well in the field and chemistry that the operator quietly stops talking about within a year. If you are running a mature asset in the GCC and your chemical opex looks suspicious, the conversation is worth having. We take it on at /services/chemistry.